Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2021

View Archived Issues

Bicycle Therapeutics targets nectin-4 and CD137 with BT-7480

WDR5 degrader MS-67 shows promise against AML in murine model

Colchicine shows promise in a rimmed vacuolar myopathy model

ADA2-mediated signaling promotes liver fibrosis in NAFLD

New and known compounds targeting PTPRD may treat AD, addiction and restless legs syndrome

Novel theranostic agent shows potential for immune-PET imaging and TRT in models of gliomas

Keaise Medicine patents TRXR inhibitors

Disarm Therapeutics discloses SARM1 inhibitors

Chinese researchers present new glucose-lowering agents

Jiangsu Chia Tai Tianqing Pharmaceutical describes HBV antivirals

Discovery of novel IDO1 inhibitors for the treatment of cancer

RAPT Therapeutics patents USP7 inhibitors

Versameb's VMB-100 shows promise for stress urinary incontinence in animal model

Defence Therapeutics' AccuVAC-PT001 COVID-19 vaccine completes toxicology studies in rabbits

SLC6A14 polymorphism tied to cystic fibrosis severity

Burning Rock to support testing of Impact's ATR inhibitor IMP-9064

Computational prodding of evolutionary history gives clues to gene variants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...